Proactive Investors - Run By Investors For Investors

Cosmos Holdings welcomes Anastasios Tzikas to the board as it looks to expand internationally

Tzikas was formerly the CEO of Singular Northern Greece SA, one of Greece’s largest software vendors
Pills in silver packaging
Cosmos is a pharmaceutical company with offices and distribution centers in Greece and the United Kingdom

Cosmos Holdings Inc (OTCQB:COSM) welcomed a new member to its advisory board as it looks to drive international growth.

Anastasios Tzikas was formerly the CEO of Singular Northern Greece SA, one of Greece’s largest software vendors.

BIG PICTURE: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

CEO Grigorios Siokas said Tzikas has a lot of experience to bring to the table.

“His tenure as former CEO of a listed multinational company and as president of well-recognized organizations makes him a great addition to our advisory board,” said Siokas in the company’s press release.

Tzikas serves as the president of several tech-focused organizations, including Thessaloniki International Fair HELEXPO SA, Federation of Hellenic Information Technology & Communications and Technopolis Thessaloniki ICT Business Park.

Cosmos is an international pharmaceutical company with offices and distribution centers in Greece and the United Kingdom.

Shares of Cosmos were down more than 5% to $7 in Wednesday afternoon training.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Article
July 02 2018

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use